The $Sst$ I Restriction Fragment Length Polymorphism of the Apolipoprotein C-III Gene in Korean Subjects

  • Youk, Hyei-Soo (Department Okcheon Public Health Center) ;
  • Kim, In-Sik (Department of Biomedical Laboratory Science, School of Medicine, Eulji University) ;
  • Kang, Sang-Sun (Department of Biology Education, Chungbuk National University) ;
  • Kang, Hee-Gyoo (Department of Biomedical Laboratory Science, College of Health Sciences, Eulji University) ;
  • Hyun, Sung-Hee (Department of Biomedical Laboratory Science, School of Medicine, Eulji University)
  • Received : 2011.12.08
  • Accepted : 2011.12.31
  • Published : 2011.12.31


The definite mechanism in the control of triglyceride metabolism is not well understood. Nowadays, it has been known that the polymorphism of apolipoprotein C-III $Sst$ I was an important candidate for contributing to the control of triglyceride metabolism. In 298 Korean women aged 30 years or more, the genotypes of apolipoprotein C-III $Sst$ I were statistically compared with total blood cholesterol, triglyceride, high density lipoprotein, fasting blood sugar and hemoglobin A1c. Multiple logistic regression analysis was carried out to compare the odd-ratios of hypertriglyceridemia, hypercholesterolemia and diabetes mellitus with them. The differences among the polymorphic types ($S_1S_1$, $S_1S_2$, and $S_2S_2$) were not statistically significant in the distribution of triglyceride, total cholesterol, high density lipoprotein, fasting blood sugar, and hemoglobin A1c. There were not statistically significant in the odds ratios of the hypertriglyceridemia, hypercholesterolemia, and diabetes mellitus, neither. Those were not statistically significant. This study did not show that there was any association between the polymorphism of apolipoprotein C-III $Sst$ I and various laboratory values-total blood cholesterol, triglyceride, high density lipoprotein, fasting blood sugar and hemoglobin A1c.


  1. Beheshti I, Hanson NQ, Copeland KR, Garg U, Tsai MY. Single-strand conformational polymorphisms (SSCP): Studies of the genetic polymorphisms of exon 4 of apolipoprotein C III. Clinical Biochem. 1995. 28: 303-307.
  2. Chen X, Tian H, Liu R. Association of serum apolipoprotein C III levels and apolipoprotein C III gene Sst I polymorphism with carotid intima-media thickness in Chinese type 2 diabetic patients. Diabetes Res Clin Pract. 2004. 66: 41-47.
  3. Choi GR, Suh SP, Song JW, Kee SJ, Shin JH, Ryang DW. Genetic variation of the apoA I-C III-AIV gene cluster in hypertriglyceridemic patients with chronic renal failure undergoing hemodialysis. J Korean Med Sci. 2000. 15: 289-294.
  4. Dallinga-Thie GM, Bu XD, van Linde-Sibenius T, Rotter JI, Lusis AJ, de Bruin TW. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res. 1996. 37: 136-147.
  5. Dammerman M, Sandkuijl LA, Hallas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3'-untranslated region polymor phisms. Proc Natl Acad Sci USA. 1993. 90: 4562-4566.
  6. Dallongeville J, Meirhaeghe A, Cottel D, Fruchart JC, Amouyel P, Helbecque N. Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. Atherosclerosis. 2000. 150: 149-157.
  7. De Silva HV, Lauer SJ, Wang J, Simonet WS, Weisgraber KH, Mahley RW, Taylor JM. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein. Eur J Biol Chem. 1994. 269: 2324-2335.
  8. Game FL, Jones AF. Coronary heart disease risk assessment in diabetes mellitus - a comparison of PROCAM and Framingham risk assessment functions. Diabetes Med. 2001. 18: 355-359.
  9. Groenendijk M, Cantor RM, de Bruin TWA, Dallinga-Thie GM. The apoAI-CIII-AIV gene cluster. Atherosclerosis. 2001. 157: 1-11.
  10. Hixson JE, Vernier DT, Powers PK. Detectionof Sst I restriction site polymorphism in human APOC3 by the polymerase chain restriction. Nucleic Acids Res. 1991. 19: 196.
  11. Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B. Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. Arterioscler Thromb Vasc Biol. 1997. 17: 1060-1066.
  12. Hodis HN, Mack WJ, LaBree L, Setzer RH, Liu C, Liu C, Alaupovic P, Kwong-Fu H, Azen SP. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. Ann Intern Med. 1996. 124: 548-556.
  13. Hong SH, Park WH, Lee CC, Song JH, Kim JQ. Association between genetic variations of apoAI-CIII-AIV cluster gene and hypertriglyceridemia subjects. Clin Chem. 1997. 43: 13-17.
  14. Jong MC, Rensen PCN, Dahlmans VEH, van der Boom H, van Berkel TJC, Havekes LM. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res. 2001. 42: 1578-1585.
  15. Kessling A, Ouellette S, Bouffard O, Chamberland A, Betard C, Selinger E, Xhignesse M, Lussier-Cacan S, Davignon J. Patterns of association between genetic variability in apolipoprotein (Apo) B, Apo AI-CIII-AIV, and cholesterol ester transfer protein gene regions and quantitative variation in lipid and lipoprotein traits: influence of gender and exogenous hormones. Am J Hum Genet. 1992. 50: 92-106.
  16. Kowal RC, Herzt J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoprotein E and C on lipoprotein binding to the low density lipoprotein receptor-related protein. J Biol Chem. 1990. 265: 10771-10779.
  17. Lorenzo FD, Rubba P, Monticelli A, Cocozza S. Coronary heart disease, echo-doppler evidence of peripheral arterial disease and polymorphism of apolipoprotein B gene and apoAI-CIII cluster. Angiology. 1993. 44: 785-790.
  18. Mahley RW, Innerarity TL, Rall SCJ, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. Plasma Lipoproprotein. 1984. 25: 1277-1294.
  19. Marcoux C, Tremblay M, Fredenrich A, Davignon J, Cohn JS. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Metabolism. 2001. 50: 112-119.
  20. Paul-Hayase H, Rosseneu M, Robinson D, van Bervliet JP, Deslypere JP, Humphries SE. Polymorphisms in the apolipoprotein (Apo) AI-CIII-AIV gene cluster: detection of genetic variation determining plasma Apo AI, Apo CIII and Apo AIV concentrations. Hum Genet. 1992. 88: 439-446.
  21. Peacock RE, Temple A, Gudnason V, Rosseneu M, Humphries SE. Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: interaction between genotype, gender, and smoking status. Genet Epidemiol. 1997. 14: 265-282.<265::AID-GEPI5>3.0.CO;2-4
  22. Ren Y, Tian H, Liu R. apo C III gene polymorphism in type 2 diabetic mellitus with hypertriglyceridemia. Chin J Endocrinol Metab. 2000. 16: 220-223.
  23. Smith JD, Brinton EA, Breslow JL. Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro. J Clin Invest. 1992. 89: 1796-1800.
  24. Talmud PJ, Humphries SE. Apolipoprotein C-III gene variation and dyslipidaemia. Curr Opin Lipidol. 1997. 8: 154-158.
  25. Wijsman EM, Brunzell JD, Jarvik GP, Austin MA, Motulsky AG, Deeb SS. Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex. Arterioscler Thromb Vasc Biol. 1998. 18: 215-226.
  26. Zeng Q, Dammerman M, Takada Y, Matsunaga A, Breslow JL, Sasaki J. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. Hum Genet. 1995. 95: 371-375.